Insider trading

Period: 120 months Stock: LH + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

162 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

162 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

162 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

162 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
162 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
162 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

162 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
5 Aug 2024
BERBERIAN LANCE EVP, CIO & CTO
Sold at will 2×
$2.77M 12,093 at 229.10
43.2%
Not planned
14 May 2024
van der Vaart Sandra D EVP, Chief Legal Officer
Sold at will 2×
$421.66K 2,000 at 210.83
26.2%
Not planned
2 May 2024
Sold at will
$50.02K 250 at 200.10
1.6%
Not planned
30 Apr 2024
Sold at will
$51.03K 250 at 204.14
1.5%
Not planned
29 Apr 2024
Wilkinson Peter J SVP, Chief Accounting Officer
Sold at will
$498.36K 2,439 at 204.33
53.9%
Sold half or more
1 Apr 2024
Schroeder Mark S EVP, Pres Diagnostics & COO
Sold on a plan
$1.41M 6,477 at 217.29
56.3%
Sold half or more
1 Apr 2024
Summy Amy B. EVP, Chief Marketing Officer
Sold on a plan
$760.52K 3,500 at 217.29
46.8%
Planned (10b5-1)
28 Mar 2024
van der Vaart Sandra D EVP, Chief Legal Officer
Sold on a plan
$770.08K 3,553 at 216.74
31.8%
Planned (10b5-1)
7 Mar 2024
Schroeder Mark S EVP, Pres Diagnostics & COO
Sold on a plan
$1.10M 5,048 at 218.45
50.1%
Sold half or more
7 Mar 2024
Summy Amy B. EVP, Chief Marketing Officer
Sold on a plan
$49.59K 227 at 218.45
5.6%
Planned (10b5-1)
21 Feb 2024
EISENBERG GLENN A Chief Financial Officer, EVP
Sold at will 4×
$7.45M 34,504 at 215.97
59.4%
Sold half or more
21 Feb 2024
DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl
Sold at will
$107.75K 500 at 215.49
12.8%
Not planned
13 Feb 2024
van der Vaart Sandra D EVP, Chief Legal Officer
Sold on a plan
$53.67K 237 at 226.45
3.0%
Planned (10b5-1)
8 Feb 2024
van der Vaart Sandra D EVP, Chief Legal Officer
Sold on a plan
$57.51K 259 at 222.06
3.3%
Planned (10b5-1)
5 Feb 2024
van der Vaart Sandra D EVP, Chief Legal Officer
Sold on a plan
$42.57K 193 at 220.57
2.5%
Planned (10b5-1)
16 Nov 2023
Wilkinson Peter J SVP, Chief Accounting Officer
Sold at will
$291.63K 1,384 at 210.71
39.9%
Not planned
8 Aug 2023
Sold at will
$1.06M 5,000 at 211.57
24.7%
Not planned
29 Jun 2023
van der Vaart Sandra D EVP, Chief Legal Officer
Sold on a plan
$50.88K 212 at 240.00
2.7%
Planned (10b5-1)
19 May 2023
Kirchgraber Paul R CEO, Covance Drug Development
Sold at will
$932.71K 4,300 at 216.91
24.9%
Not planned
18 May 2023
Schroeder Mark S EVP, Pres Diagnostics & COO
Sold on a plan
$325.16K 1,500 at 216.77
18.3%
Planned (10b5-1)
31 Mar 2023
Schroeder Mark S EVP, President-Diagnostics Lab
Sold on a plan
$879.98K 3,897 at 225.81
36.8%
Planned (10b5-1)
21 Feb 2023
Kirchgraber Paul R CEO, Covance Drug Development
Sold, plan not stated
$2.00M 8,000 at 250.58
46.9%
14 Feb 2023
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$76.52K 309 at 247.63
4.4%
7 Feb 2023
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$99.39K 409 at 243.01
5.8%
7 Feb 2023
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$53.22K 219 at 243.01
3.9%
3 Feb 2023
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$82.26K 324 at 253.90
4.6%
3 Feb 2023
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$43.92K 173 at 253.90
3.1%
8 Nov 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$259.66K 1,116 at 232.67
14.3%
26 Sep 2022
EISENBERG GLENN A Chief Financial Officer, EVP
Sold, plan not stated 4×
$5.27M 25,000 at 210.62
47.9%
7 Sep 2022
Caveney Brian J EVP, President of Diagnostics
Bought
$10.25K 44 at 231.20
0.3%
Largest buy in 3 yrs
3 Aug 2022
EISENBERG GLENN A Chief Financial Officer, EVP
Sold, plan not stated 3×
$8.15M 32,100 at 253.94
38.1%
1 Aug 2022
Wilkinson Peter J SVP, Chief Accounting Officer
Sold, plan not stated 3×
$665.63K 2,576 at 258.40
57.7%
Sold half or more
7 Jun 2022
Caveney Brian J EVP, President of Diagnostics
Bought
$10.17K 42 at 242.19
0.3%
First buy on file
29 Mar 2022
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$678.64K 2,449 at 277.11
31.7%
29 Mar 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$652.87K 2,356 at 277.11
26.3%
25 Mar 2022
Sold, plan not stated
$156.14K 572 at 272.98
8.2%
10 Mar 2022
Summy Amy B. EVP, Chief Marketing Officer
Sold, plan not stated
$65.29K 249 at 262.21
49.9%
16 Feb 2022
NEUPERT PETER M Director
Bought 3×
$922.82K 3,500 at 263.66
51.8%
First buy on file
15 Feb 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$56.71K 207 at 273.98
3.0%
15 Feb 2022
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$56.71K 207 at 273.98
3.8%
7 Feb 2022
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$60.47K 218 at 277.38
4.0%
7 Feb 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$56.59K 204 at 277.38
3.0%
3 Feb 2022
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$46.75K 172 at 271.81
3.2%
3 Feb 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$43.76K 161 at 271.81
2.5%
15 Dec 2021
Sold, plan not stated 4×
$151.13K 500 at 302.26
7.4%
15 Sep 2021
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$1.34M 4,500 at 296.78
46.1%
7 Jun 2021
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$1.20M 4,500 at 266.56
46.2%
6 May 2021
Kirchgraber Paul R CEO, Covance Drug Development
Sold, plan not stated
$691.38K 2,500 at 276.55
24.2%
3 May 2021
Sold, plan not stated
$699.80K 2,600 at 269.16
14.3%
30 Mar 2021
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$204.53K 812 at 251.88
13.4%
Showing 51–100 of 162. ← Newer Page 2 of 4 Older →